Close Menu

NEW YORK – Promega said on Thursday that it has signed a license agreement for MilliporeSigma's foundational CRISPR genome editing technology.

Under the terms of the agreement, Promega will use the CRISPR technology to create new research products for investigating endogenous biology, including products for drug development. The company is aiming to develop tools that will allow researchers to better determine physiological levels of protein expression, providing a more accurate understanding of protein behavior.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.

The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.

Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.

In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.